Is Auvelity available in Europe (including Poland) in 2024?
Auvelity (dextromethorphan/ bupropion) is an FDA-approved treatment for major depressive disorder in the US, but the provided information does not state whether it is marketed in Europe or Poland as of 2024. Without country-specific authorization/launch details, availability cannot be confirmed from the provided material.
How can I check Auvelity’s real-time approval and launch status in Poland and other EU countries?
The fastest way to verify whether Auvelity is marketed (and from when) in a specific EU country is to check:
- the local medicines authority/country registry for marketing authorization and reimbursement status, and
- Auvelity’s marketing authorization status in the EU (for countries where it is licensed).
If you share which country list you care about (e.g., Poland plus 5–10 nearby markets), I can help you map what to check for each one.
Could it be authorized but not sold in Poland yet?
Yes. Even if a product is authorized, it may still be delayed for reasons like:
- reimbursement and pricing negotiations,
- local distributor/launch timing,
- formulary placement.
So “authorized” and “available to patients” can differ.
What would count as “available” in Poland for patients?
People usually mean one of these:
- stocked by pharmacies with a valid prescription,
- reimbursed by the national health system (or available only commercially at full cost),
- available via hospital/clinic pharmacy channels.
Those statuses come from different sources than basic approval.
If you want, I can narrow this to a clear 2024 answer
Tell me whether you mean:
1) marketing authorization granted in 2024,
2) first launch date in Poland in 2024, or
3) whether patients could routinely get it on prescriptions in 2024.
Also confirm the exact market scope: Poland only, or “Europe” as a set of specific countries.